Companies

U.S. Food and Drug Administration

Follow the latest coverage, related explainers and connected technology stories.

Latest coverage

CN
Startup Develops Miniature Human Intestines to Test Drugs Instead of Animal Models

Startup Develops Miniature Human Intestines to Test Drugs Instead of Animal Models

Intero Biosystems sells laboratory-grown organoid models of human intestines to pharmaceutical and biotechnology companies, aiming to provide a model closer to human biology and use it alongside or, in some cases, instead of animal testing. The company is still in the second of three stages for proving GastroScreen’s ability to predict drug responses in humans.

CN
Philips Updates Lumify Ultrasound Device Instructions After Reports of 4 Deaths

Philips Updates Lumify Ultrasound Device Instructions After Reports of 4 Deaths

Philips updated the instructions for using its portable Lumify ultrasound system after receiving reports of eight serious injuries and four deaths associated with delays in using the device. The issue is linked to a software application that may request re-registration of the probe in environments without Wi‑Fi or cellular connectivity.

CN
U.S. Food and Drug Administration Approves Expandable Heart Valve for Children from Edwards

U.S. Food and Drug Administration Approves Expandable Heart Valve for Children from Edwards

Edwards Lifesciences' Autus valve has received FDA approval, with the possibility of later expansion using a balloon catheter as the child grows, potentially reducing the need for repeated open-heart surgeries. The decision was based on a study involving 62 children, with follow-up planned for 10 years.

CN
U.S. Food and Drug Administration Opens Comment Period on 2027 Medical Device Guidance Priorities

U.S. Food and Drug Administration Opens Comment Period on 2027 Medical Device Guidance Priorities

The U.S. Food and Drug Administration identified the guidance lists that the Center for Devices and Radiological Health plans to publish or develop during fiscal year 2027 and opened a comment period through November 30, 2026. The plan includes lists of priorities, potential resources, and documents under development.

CN
Trump’s FDA Nominee Pledges to Follow the Law in Vaccine and Abortion Drug Decisions

Trump’s FDA Nominee Pledges to Follow the Law in Vaccine and Abortion Drug Decisions

Heidi Overton, Donald Trump’s nominee to lead the U.S. Food and Drug Administration, told the Senate that she would follow the law in decisions involving vaccines and the drug mifepristone, and pledged to accelerate early drug research and confront the rise of China’s biotechnology sector.

CN
FDA Advisory Committee Supports Grail’s Test for Detecting Multiple Cancers

FDA Advisory Committee Supports Grail’s Test for Detecting Multiple Cancers

An independent expert committee voted that the potential benefits of Grail’s Galleri test outweigh its risks, paving the way for an FDA decision while emphasizing that it does not replace recommended cancer screenings.

CN
Oura Seeks to Raise $2.2 Billion Through IPO Amid Expansion of Smart Rings in Digital Health

Oura Seeks to Raise $2.2 Billion Through IPO Amid Expansion of Smart Rings in Digital Health

Oura filed for an initial public offering that could be worth up to $2.2 billion, offering 50 million shares at an estimated price of between $40 and $44 per share. The offering comes as the company expands its health features, while facing regulatory questions and a proposed lawsuit concerning the accuracy of sleep tracking.

CN
FDA Funds Test of Using Language Models to Evaluate AI-Generated Radiology Reports

FDA Funds Test of Using Language Models to Evaluate AI-Generated Radiology Reports

The U.S. Food and Drug Administration awarded Cognita Imaging a $1.29 million research contract to test the ability of a group of large language models to evaluate radiology reports produced by artificial intelligence systems. The project aims to measure hallucinations and omissions and identify cases requiring review by a radiologist.

CN
FDA Advisory Committee to Examine the Use of Pathogen-Agnostic Sequencing in Emergency Response

FDA Advisory Committee to Examine the Use of Pathogen-Agnostic Sequencing in Emergency Response

The U.S. Food and Drug Administration will hold a public meeting on November 19, 2026, to examine the scientific, clinical, and public health dimensions of using sequencing technologies capable of detecting known or unknown pathogens. The meeting will discuss test design and the bioinformatics systems needed to address ongoing changes in genetic sequences.

CN
New FDA Requirements in eSTAR Move Usability Factors from the Testing Box to the Risk File

New FDA Requirements in eSTAR Move Usability Factors from the Testing Box to the Risk File

The FDA’s 2026 guidance, incorporated into the eSTAR v7.0 form, states that companies are required to demonstrate the acceptability of use-related risks associated with medical devices, not merely submit a human factors testing report. The level of risk and whether use tasks are critical determine the amount of evidence and documentation required in the submission file.

CN
FDA Explains How Regulatory Authorities Rely on Its Decisions in the Medical Device Field

FDA Explains How Regulatory Authorities Rely on Its Decisions in the Medical Device Field

CDRH has launched a reference portal explaining regulatory reliance programs for assessments and decisions by other regulatory authorities, focusing on using FDA data without transferring decision-making responsibility or reducing safety requirements. The portal provides guidance on verifying the identity of devices and their manufacturing sites and monitoring post-market safety.

CN
FDA Guide for Small Businesses to Obtain Medical Device Fee Reductions or Waivers

FDA Guide for Small Businesses to Obtain Medical Device Fee Reductions or Waivers

The FDA explains the Small Business Determination program mechanism for companies seeking to reduce or waive medical device application fees, with different financial thresholds, documents, and deadlines depending on the type of benefit. Applications must be submitted electronically through the User Fee System and CDRH Portal, and status must be renewed each fiscal year.

CN
FDA Warns Against Using Clear Aligners Without Medical Supervision

FDA Warns Against Using Clear Aligners Without Medical Supervision

The U.S. Food and Drug Administration explains that clear aligners are prescription devices requiring evaluation and monitoring by a dentist or orthodontist. It warns against products sold directly to consumers without professional supervision, explains their risks, and describes how to verify device clearance.

CN
FDA Updates List of AI-Enabled Medical Devices and Prepares to Track Foundation Models

FDA Updates List of AI-Enabled Medical Devices and Prepares to Track Foundation Models

The U.S. Food and Drug Administration has updated its list of AI-enabled medical devices authorized for marketing in the United States, emphasizing that the list is not exhaustive and does not represent a complete database of all devices. The agency is exploring future mechanisms to identify devices that incorporate foundation models, including large language models and multimodal systems.

CN
Boston Scientific Recalls Imager II Catheters After Tip Detachment Risk

Boston Scientific Recalls Imager II Catheters After Tip Detachment Risk

Boston Scientific halted the distribution and use of Imager II Angiographic Catheters after discovering that they were manufactured with low levels of tip bonding materials, which could lead to tip deterioration or detachment inside a blood vessel. The company reported two serious injuries linked to the issue as of July 16, while the FDA issued an early alert about it.

CN
Medtronic Recalls Esophageal pH Monitoring Capsules After 184 Serious Injuries Reported

Medtronic Recalls Esophageal pH Monitoring Capsules After 184 Serious Injuries Reported

Medtronic recalled a group of Bravo CF capsules used to monitor esophageal acidity after a defect was linked to 184 serious injuries, with no deaths reported through August 10, 2026. The defect may cause the capsule to fail to attach or detach, with risks including airway obstruction, esophageal perforation, and a retained foreign body inside the patient.

CN
FDA Requests Public Comment on Classifying Certain Medical Device Accessories as Class I Devices

FDA Requests Public Comment on Classifying Certain Medical Device Accessories as Class I Devices

The FDA’s Center for Devices and Radiological Health has issued a proposed list of medical device accessories that may be eligible for independent classification as Class I devices and opened a comment period through October 16, 2026. The action does not mean that the classification has already been approved; rather, it aims to identify accessories for which general controls are sufficient to provide reasonable assurance of safety and effectiveness.

CN
Abbott Receives U.S. Authorization for Sensor That Monitors Glucose and Ketones Together

Abbott Receives U.S. Authorization for Sensor That Monitors Glucose and Ketones Together

The U.S. Food and Drug Administration granted Abbott de novo authorization for the Libre Duo 10 Day wearable sensor, which can continuously monitor glucose and ketones in people with diabetes. The company plans to launch it in the United States during 2026, while its price and insurance coverage remain undisclosed.

CN
FDA Selects First Participants in READI-Home Challenge to Develop Devices That Reduce Hospital Readmissions

FDA Selects First Participants in READI-Home Challenge to Develop Devices That Reduce Hospital Readmissions

The U.S. Food and Drug Administration has selected initial participants to advance to the interaction phase of the READI-Home Challenge, which aims to accelerate the development of medical devices for home use after hospital discharge. The current list includes a system for monitoring electrical brain activity and a therapeutic vibrating mattress for infants, while applications continue to be accepted through September 30, 2026.

CN
FDA Authorizes Claria System for Tissue Containment During Laparoscopic Uterine Surgery and Reaffirms Risks of Uncontained Morcellation

FDA Authorizes Claria System for Tissue Containment During Laparoscopic Uterine Surgery and Reaffirms Risks of Uncontained Morcellation

The U.S. Food and Drug Administration authorized the Claria System for marketing, a device that combines tissue morcellation and containment during certain laparoscopic uterine surgeries. The agency emphasizes that electromechanical morcellators should be used only in selected patients and with a compatible containment system because of the risk of spreading undetected uterine cancer.